Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Possible Unmet Need: Pneumococcal Vaccination in the Workplaces-A Systematic Review of Invasive Pneumococcal Disease Among Shipyard Workers.

Vaccines·2026
Same author

Neonatal PBPK model of midazolam and its metabolites for perinatal asphyxia and therapeutic hypothermia.

British journal of clinical pharmacology·2026
Same author

Prevention of Respiratory Syncytial Virus-Related Hospitalization in Newborns.

JAMA·2026
Same author

In Reply: Disease Spectrum of Human Metapneumovirus Infections in Infants and Young Children: Data From a Prospective Multicenter Study in Germany.

The Pediatric infectious disease journal·2026
Same author

A Rare Case of Neonatal Rib Osteomyelitis: Diagnostic Challenges and Successful Conservative Management.

The Pediatric infectious disease journal·2026
Same author

Did Nirsevimab Shift Pediatric Hospitalizations Due to Lower Respiratory Tract Infections? A Nationwide Italian Study (2024-2025).

Viruses·2026
Same journal

Determinants of Severity in Pediatric Viral Lower Respiratory Tract Diseases From Emergency Department Presentation to Hospital Course.

The Pediatric infectious disease journal·2026
Same journal

Oropharyngeal Colonization by Kingella kingae and Septic Arthritis in Children 6-48 Months of Age: A Portuguese Multicenter Case-control Study.

The Pediatric infectious disease journal·2026
Same journal

Trends in Late-onset Sepsis in Very Low Birth Weight Preterm Infants in the Brazilian Network on Neonatal Research: A 10-year Cohort Study.

The Pediatric infectious disease journal·2026
Same journal

Severe Mycoplasma-induced Rash and Mucositis Mimicking Stevens-Johnson Syndrome Treated With Steroid Pulse Therapy: A Case Highlighting Diagnostic Challenges and Therapeutic Considerations.

The Pediatric infectious disease journal·2026
Same journal

Clindamycin Prophylaxis in Pediatric Punctate Outer Retinal Toxoplasmosis.

The Pediatric infectious disease journal·2026
Same journal

Burden of COVID-19 in Korean Children: A Retrospective Observational Study Using Real-world Data.

The Pediatric infectious disease journal·2026
See all related articles

Related Experiment Video

Updated: May 17, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

Optimizing micafungin dosing in children

Wei Zhao, William W Hope, Paolo Manzoni

    The Pediatric Infectious Disease Journal
    |October 17, 2012
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
    06:14

    Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

    Published on: October 15, 2017

    Galleria mellonella as an Antimicrobial Screening Model
    06:19

    Galleria mellonella as an Antimicrobial Screening Model

    Published on: October 11, 2024

    Related Experiment Videos

    Last Updated: May 17, 2026

    Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
    08:54

    Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

    Published on: February 14, 2018

    Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
    06:14

    Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

    Published on: October 15, 2017

    Galleria mellonella as an Antimicrobial Screening Model
    06:19

    Galleria mellonella as an Antimicrobial Screening Model

    Published on: October 11, 2024